期刊文献+

腹腔镜辅助胃癌根治术联合新辅助化疗对机体免疫功能及炎性反应的影响 被引量:5

Effect of laparoscope-assisted radical gastrectomy combined with neoadjuvant chemotherapy on immune function and inflammatory response
下载PDF
导出
摘要 目的:研究腹腔镜辅助胃癌根治术联合新辅助化疗对机体免疫功能及炎性反应的影响。方法:选择170例胃癌患者,随机分为观察组和对照组各85例;对照组给予腹腔镜辅助胃癌根治术治疗,观察组联合给予新辅助化疗治疗,比较两组的治疗效果。结果:观察组的治疗有效率为89.41%,高于对照组的72.94%(P<0.05);治疗后两组的CD_4^+、CD_3^+以及CD_4^+/CD_8^+均升高(P<0.05),观察组高于对照组(P<0.05);治疗后两组的白介素-6、肿瘤坏死因子-α以及白介素-23水平均降低(P<0.05),观察组低于对照组(P<0.05)。结论:腹腔镜辅助胃癌根治术联合新辅助化疗可以提高对胃癌的治疗效果,提高机体免疫功能,且降低炎性反应。 Objective:To study the effect of laparoscope-assisted radical gastrectomy combined with neoadjuvant chemotherapy on immune function and inflammatory response.Methods:170 patients with gastric cancer in our hospital were randomly divided into two groups,85 cases in each group.The control group was treated with laparoscope-assisted radical gastrectomy,and the observation group was additionally treated with neoadjuvant chemotherapy.The clinical effect of the two groups was compared.Results:The effective rate of the observation group was 89.41 %,which was significantly higher than that of the control group(72.94 %)(P〈0.05).After treatment,CD_4~+,CD_3~+ and CD_4~+/CD_8~+ were significantly increased in the two groups(P〈0.05),and the increase in the observation group was more obvious(P〈0.05).After treatment,the levels of interleukin-6,tumor necrosis factor-α and interleukin-23 in the two groups were significantly decreased(P〈0.05),and the decrease levels in the observation group were significantly lower than those in the control group(P〈0.05).Conclusion:Laparoscope-assisted radical gastrectomy combined with neoadjuvant chemotherapy can improve the clinical effect of gastric cancer,improve the immune function,and reduce the inflammatory response.
作者 王磊 穆雷霞
机构地区 庆阳市人民医院
出处 《包头医学院学报》 CAS 2018年第1期77-78,共2页 Journal of Baotou Medical College
关键词 腹腔镜辅助胃癌根治术 新辅助化疗 机体免疫功能 炎性反应 Laparoscope -assisted radical gastrectomy Neoadjuvant chemotherapy Immune function Inflammatory response
  • 相关文献

参考文献4

二级参考文献43

  • 1勒世联.不同化疗方案一线治疗老年晚期胃癌的近期疗效分析[J].中国生化药物杂志,2014,34(1):108-110. 被引量:9
  • 2KatherineDCrew,AlfredINeugut.Epidemiology of gastric cancer[J].World Journal of Gastroenterology,2006,12(3):354-362. 被引量:188
  • 3Ling Yang.Incidence and mortality of gastric cancer in China[J].World Journal of Gastroenterology,2006,12(1):17-20. 被引量:345
  • 4Lee JH,Kim SH,Oh SY,et al. Third-line docetaxel chemothera-py for recurrent and metastatic gastric cancer[J]. Korean J In-tern Med,2013,28(3) :314-321.
  • 5Luo H, Yu Z,Gao H,et al. Efficacy and tolerability of docetaxeland cisplatin plus S-l for advanced gastric cancer[J]. J BUON,2013,18(1):154-161.
  • 6Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit withdocetaxel plus fluorouracil and cisplatin compared with cisplatin andfluorouracil in a phase trial of advanced gastric or gastroesophagealcancer adenocarcinoma: the V-325 Study Group [J]. J Clin Oncol,2007,25C22):3205-3209.
  • 7Kanat O,O’Neil BH. Metastatic gastric cancer treatment:a lit-tle slow but worthy progress[J]. Med Oncol,2013.30(1) :464.
  • 8Huang D,Ba Y, Xiong J, et al. A multicentre randomised trialcomparing weekly paclitaxel + S-l with weekly paclitaxel +5-fluorouracil for patients with advanced gastric cancer[J]. Eur JCancer,2013,49(14):2995-3002.
  • 9Van Cutsem E,Moiseyenko VM,Tjulandin S,et al. Phase HI study ofdocetaxel and cisplatin plus fluorouracil compared with cisplatin and flu-orouracil as first-line therapy for advanced gastric cancer:a report of theV325 study group[J], J Clin Oncol,2006,24(31) :4991-4997.
  • 10Kim YS,Sym SJ * Park SH, et al. A randomized phase II studyof weekly docetaxel/cisplatin versus weekly docetaxel/oxalipla-tin as first-line therapy for patients with advanced gastric cancer[J]. Cancer Chemother Pharmacol,2014,73(1) : 163-169.

共引文献236

同被引文献31

引证文献5

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部